Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38579681.
- Also identified by DOI 10.1016/j.stem.2024.03.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-CD19 CAR T cells were among the last decade's scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis.<sup>1</sup>.
Medical subject headings
- Lupus Erythematosus, Systemic
- Neoplasms
- Immunotherapy, Adoptive